Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial


Galsky M. D. , Arranz Arija J. A. , Bamias A., Davis I. D. , De Santis M., Kikuchi E., ...Daha Fazla

LANCET, cilt.395, sa.10236, ss.1547-1557, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 395 Konu: 10236
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/s0140-6736(20)30230-0
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.1547-1557

Özet

Background Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.